They can issue as many fluff PRs as possible but it won’t move the stock unless they bring significant non dilutive funding from big pharma. Unfortunately, this ain’t happening. So, everything else is just noise at this point. The shorts will slam the stock and continue to do so because they know that LP will be forced to dilute in pennies for years to come. Revenue will be insignificant as well. Every quarterly revenue report post UK approval will be an opportunity for shorts to pound the stock. Will work without fail, in addition to endless dilution.
Market Data 
Markets 
AI
